Plasmodium vivax Malaria Relapse Risk Depends on Transmission Intensity: Evidence From a Longitudinal Study in Northwest Thailand

dc.contributor.authorChu C.S.
dc.contributor.authorLwin K.M.
dc.contributor.authorBurgoine K.
dc.contributor.authorPhyo A.P.
dc.contributor.authorTurner C.
dc.contributor.authorSan T.
dc.contributor.authorAung A.A.
dc.contributor.authorWin H.H.
dc.contributor.authorHtoo K.
dc.contributor.authorSoe N.L.
dc.contributor.authorChristina N.
dc.contributor.authorThan H.H.
dc.contributor.authorDah N.
dc.contributor.authorPilaseng K.
dc.contributor.authorWiladpaingern J.
dc.contributor.authorProux S.
dc.contributor.authorMukaka M.
dc.contributor.authorParker D.M.
dc.contributor.authorCarrara V.I.
dc.contributor.authorNosten F.
dc.contributor.authorWhite N.J.
dc.contributor.correspondenceChu C.S.
dc.contributor.otherMahidol University
dc.date.accessioned2026-02-06T18:26:24Z
dc.date.available2026-02-06T18:26:24Z
dc.date.issued2026-01-01
dc.description.abstractBackground In northwest Thailand, the provision of radical cure to prevent relapses of Plasmodium vivax malaria has decreased P vivax caseloads and decreased transmission. While malaria control measures were increased, we performed a prospective observational rolling cohort study to describe the changing incidence of P vivax malaria and the associated recurrence rates. Methods Healthy nonpregnant glucose-6-phosphate dehydrogenase–normal volunteers who had symptomatic P vivax infection in the previous 12–24 months, but who had not received radical cure, were recruited. Supervised primaquine was given daily for 14 days (0.5 mg base/kg/day). Participants were followed 4 and 8 weeks later, then every 2 months until they developed symptomatic or asymptomatic P vivax malaria. Consultation for febrile illnesses was encouraged between follow-up visits. Participants who developed P vivax malaria were replaced with matched volunteers to maintain a continuous cohort of 200 participants. Results From March 2010 until September 2014, 380 healthy adults and children were enrolled. Ninety-two individuals developed P vivax malaria, 25 within 4 months of enrollment. The annual incidence of P vivax malaria infection decreased from 0.19 in 2010 to 0.09 infections per person-year in 2014. The primaquine failure rate (P vivax malaria within 4 months of treatment) was 75% less than predicted based on earlier assessments that assumed a constant hypnozoite reservoir. Conclusions Declining P vivax transmission reduces the hypnozoite reservoir in the population and the hypnozoite burden in an individual. This increases the apparent efficacy of radical cure in preelimination settings.
dc.identifier.citationOpen Forum Infectious Diseases Vol.13 No.1 (2026)
dc.identifier.doi10.1093/ofid/ofaf667
dc.identifier.eissn23288957
dc.identifier.scopus2-s2.0-105028023166
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/114666
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titlePlasmodium vivax Malaria Relapse Risk Depends on Transmission Intensity: Evidence From a Longitudinal Study in Northwest Thailand
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105028023166&origin=inward
oaire.citation.issue1
oaire.citation.titleOpen Forum Infectious Diseases
oaire.citation.volume13
oairecerif.author.affiliationUniversity of California, Irvine
oairecerif.author.affiliationNuffield Department of Medicine
oairecerif.author.affiliationUniversité de Genève Faculté de Médecine
oairecerif.author.affiliationMahidol Oxford Tropical Medicine Research Unit

Files

Collections